Purpose:
Recently, it has been demonstrated that lectin-like ox-LDL receptor-1 (LOX-1) is expressed on chondrocytes and suggested in vitro and vivo that its ligand ox-LDL play some role in degeneration of articular cartilage. To investigate whether oxidized low-density lipoprotein (ox-LDL) binding to lectin-like ox-LDL receptor 1 (LOX-1) enhances monocyte chemoattractant protein 1 (MCP-1) expression in cultured human articular chondrocytes (HACs). Furthermore, to ascertain whether the ox-LDL-induced MCP-1 upregulation is mediated by NF-kappaB activation. Methods: The time course and dose response of MCP-1 mRNA expression and MCP-1 protein release into medium following ox-LDL stimulation were investigated using RT-PCR and ELISA, respectively. HACs were also preincubated with anti-human LOX-1 mAb (TS92) and specific NF-kappaB inhibitors (BAY11-7082, MG132, and SN50). Whole cell extracts from HACs treated for the indicated periods with ox-LDL and preincubated with the TS92 were prepared, and NF-kappaB activation (p65 DNA binding activity) following ox-LDL stimulation was investigated by ELISA. Results: LOX-1 mRNA expression in HACs was confirmed by RT-PCR. Ox-LDL significantly increased MCP-1 mRNA and protein expression levels in a time-and dose-dependent manner, which was suppressed markedly by pretreatment with TS92 and NF-kappaB inhibitors (Fig. 1 ). Ox-LDL stimulation activated NF-kappaB in HACs in a dose-dependent manner, which was suppressed by TS92 pretreatment (Fig. 2) . NF-kappaB inhibitors significantly suppressed ox-LDL-induced MCP-1 expression. Conclusions: It has been reported that chemokines produced by chondrocytes and chemokine receptors expressed on chondrocytes play an important role in pathogenesis of arthritis through intra-articular recruitment of monocytes/macrophages and the activation of matrix degrading enzymes. Our results suggest that the ox-LDL binding to LOX-1 enhances MCP-1 expression in human articular chondrocytes through activation of NF-kappaB and supports the hypothesis that ox-LDL deposition in cartilage and its receptor LOX-1 expression on chondrocytes are involved in degeneration of cartilage in osteoarthritis and rheumatoid arthritis. Purpose: It has been proposed that diacerhein acts as a slowacting, symptom-modifying and perhaps as a disease-structure modifying drug in the treatment of osteoarthritis (OA), although its effects on cartilage and synovial catabolic program remain poorly studied. This work was designed to simultaneously study the effects of diacerhein and that of conventional symptomatic drugs, like NSAIDs, on the synthesis of inflammation and structural mediators in OA chondrocytes and synoviocytes in culture. Methods: Chondrocytes and synoviocytes were obtained from joint specimens of OA patients who underwent total knee replacement surgery. We used quiescent cells stimulated with 10 U/ML IL-1β, and studied the effects of diacerhein (10-5M), celecoxib (CBX, 10-6M), diclofenac (DCF, 10-6M), meloxicam (MXC, 10-6M) and indomethacin (IND, 10-6M) in the release of prostaglandin (PG) E2 and nitric oxide (NO), the expression of cyclooxigenase (COX)-2, the accumulation of metalloproteinase (MMP)-1 and MMP-13, and the activation of the nuclear factor kappa B (NF-kB). All drugs were tested at the mean peak plasma concentration (Cmax) observed after oral administration of a therapeutic dose. Results: The activation of NF-kB binding induced by IL-1 was inhibited by diacerhein, both in chondrocytes and synoviocytes. All of the NSAIDs used in these experiments also inhibited the activation of NF-kB induced by IL-1, although IND only showed this effect on chondrocytes. Regarding the prostaglandin system, we showed that diacerhein did not revert the increase in COX-2
DIACERHEIN EXERTS A PARTIAL CONTROL ON THE CATABOLIC PROGRAM OF HUMAN OSTEOARTHRITIC CHONDROCYTES BUT NOT ON SYNOVIAL FIBROBLAST

